Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Ephrin type-A receptor 2

3

Platelet-derived growth factor receptor beta

3

SRC

3

Stem cell growth factor receptor

3

Tyrosine-protein kinase ABL

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2006

3

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute lymphoblastic leukemia

3

Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bristol-Myers Squibb

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

PUBCHEM

4

EPA CompTox

3

CHEBI

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Protein kinase inhibitors

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DASATINIB ANHYDROUS

X78UG0A0RN

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 2006

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Ephrin type-A receptor 2

Tyrosine-protein kinase ABL

Conditions:

Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)

Acute lymphoblastic leukemia

Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...

sistance/intolerance. It’s used for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. While imatinib remains a frontline therapy for CML, patients with advanced disease frequently develop resistance to imatinib therapy through multiple mechanisms. Dasatinib is also undergoing preclinical evaluation for its potential as a therapy against multiple myeloma. Bristol-Myers Squibb has a composition-of-matter patent covering this research approach that will expire in 2020. Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.

GLYCERYL 2-CAPRYLATE

O8TCW8DUW8

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Dasatinib Laurylsulfate

FY77PS0C4O

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 2006

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Ephrin type-A receptor 2

Tyrosine-protein kinase ABL

Conditions:

Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)

Acute lymphoblastic leukemia

Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...

sistance/intolerance. It’s used for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. While imatinib remains a frontline therapy for CML, patients with advanced disease frequently develop resistance to imatinib therapy through multiple mechanisms. Dasatinib is also undergoing preclinical evaluation for its potential as a therapy against multiple myeloma. Bristol-Myers Squibb has a composition-of-matter patent covering this research approach that will expire in 2020. Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.

DASATINIB

RBZ1571X5H

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 2006

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Platelet-derived growth factor receptor beta

Stem cell growth factor receptor

Ephrin type-A receptor 2

Tyrosine-protein kinase ABL

Conditions:

Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)

Acute lymphoblastic leukemia

Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired re...

sistance/intolerance. It’s used for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. While imatinib remains a frontline therapy for CML, patients with advanced disease frequently develop resistance to imatinib therapy through multiple mechanisms. Dasatinib is also undergoing preclinical evaluation for its potential as a therapy against multiple myeloma. Bristol-Myers Squibb has a composition-of-matter patent covering this research approach that will expire in 2020. Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1